Clinical Impact of Natural Killer Cell Reconstitution After Allogeneic Hematopoietic Transplantation

Overview

Journal Semin Immunopathol

Publisher Springer

Specialties Allergy & Immunology
Pathology

Date 2008 Nov 13

PMID 19002464

Citations 11

Authors

Andrea Velardi

Loredana Ruggeri

Antonella Mancusi

Emanuela Burchielli

Katia Perruccio

Franco Aversa

Massimo F Martelli

Affiliations

Soon will be listed here.

Abstract

Although the optimal donor for allogeneic hematopoietic stem cell transplantation is a human leukocyte antigen (HLA)-matched sibling, 75% of patients do not have a match and alternatives are matched unrelated volunteers, unrelated umbilical cord blood units, and full HLA-haplotype-mismatched family members. This review will focus on the open issues of allogeneic hematopoietic transplantation and on the benefits of natural killer (NK) cell alloreactivity and its underlying mechanisms. Donor-versus-recipient NK cell alloreactivity derives from a mismatch between inhibitory receptors for self major histocompatibility complex (MHC) class I molecules on donor NK clones and the MHC class I ligands on recipient cells. These NK clones sense the missing expression of the self MHC class I allele on the allogeneic targets ("missing self") and mediate alloreactions. Here, we review the translation of NK cell allorecognition into the clinical practice of allogeneic hematopoietic transplantation and discuss how it has opened innovative perspectives in the cure of leukemia.

Citing Articles

Clinical Characteristics and Outcome Analysis for HLA Loss Patients Following Partially Mismatched Related Donor Transplantation Using HLA Chimerism for Loss of Heterozygosity Analysis by Next-Generation Sequencing.

Wang A, Li W, Zhao F, Zheng Z, Yang T, Wang S Cell Transplant. 2022; 31:9636897221102902.

PMID: 35670196 PMC: 9178980. DOI: 10.1177/09636897221102902.

[Mechanism of relapse and its therapeutic strategies after allogeneic hematopoietic stem cell transplantation].

Wu H, Zhao Y, Huang H Zhonghua Xue Ye Xue Za Zhi. 2021; 42(10):869-877.

PMID: 34788930 PMC: 8607022. DOI: 10.3760/cma.j.issn.0253-2727.2021.10.014.

KIR Receptors as Key Regulators of NK Cells Activity in Health and Disease.

Debska-Zielkowska J, Moszkowska G, Zielinski M, Zielinska H, Dukat-Mazurek A, Trzonkowski P Cells. 2021; 10(7).

PMID: 34359951 PMC: 8303609. DOI: 10.3390/cells10071777.

High-Risk Leukemia: Past, Present, and Future Role of NK Cells.

Mavers M, Bertaina A J Immunol Res. 2018; 2018:1586905.

PMID: 29850617 PMC: 5925205. DOI: 10.1155/2018/1586905.

How important is NK alloreactivity and KIR in allogeneic transplantation?.

Shaffer B, Hsu K Best Pract Res Clin Haematol. 2016; 29(4):351-358.

PMID: 27890259 PMC: 5896016. DOI: 10.1016/j.beha.2016.10.010.

References

Spierings E, Goulmy E . Expanding the immunotherapeutic potential of minor histocompatibility antigens. J Clin Invest. 2005; 115(12):3397-400. PMC: 1297265. DOI: 10.1172/JCI27094. View

Kroger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A . Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. Br J Haematol. 2005; 129(5):631-43. DOI: 10.1111/j.1365-2141.2005.05513.x. View

Kroger N, Binder T, Zabelina T, Wolschke C, Schieder H, Renges H . Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation. Transplantation. 2006; 82(8):1024-30. DOI: 10.1097/01.tp.0000235859.24513.43. View

Lanier L . Up on the tightrope: natural killer cell activation and inhibition. Nat Immunol. 2008; 9(5):495-502. PMC: 2669298. DOI: 10.1038/ni1581. View

Volpi I, Perruccio K, Tosti A, Capanni M, Ruggeri L, Posati S . Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants. Blood. 2001; 97(8):2514-21. DOI: 10.1182/blood.v97.8.2514. View

Kolb H, Schmid C, Barrett A, Schendel D . Graft-versus-leukemia reactions in allogeneic chimeras. Blood. 2003; 103(3):767-76. DOI: 10.1182/blood-2003-02-0342. View

Valiante N, Uhrberg M, Shilling H, Arnett K, DAndrea A, Phillips J . Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors. Immunity. 1998; 7(6):739-51. DOI: 10.1016/s1074-7613(00)80393-3. View

Vilches C, Parham P . KIR: diverse, rapidly evolving receptors of innate and adaptive immunity. Annu Rev Immunol. 2002; 20:217-51. DOI: 10.1146/annurev.immunol.20.092501.134942. View

Saarinen-Pihkala U, Gustafsson G, Ringden O, Heilmann C, Glomstein A, Lonnerholm G . No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission. J Clin Oncol. 2001; 19(14):3406-14. DOI: 10.1200/JCO.2001.19.14.3406. View

10.

CUDKOWICZ G, Bennett M . Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med. 1971; 134(6):1513-28. PMC: 2139114. DOI: 10.1084/jem.134.6.1513. View

11.

Thomas R, Yamada E, Alter G, Martin M, Bashirova A, Norman P . Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation?. J Immunol. 2008; 180(10):6743-50. PMC: 2689389. DOI: 10.4049/jimmunol.180.10.6743. View

12.

Pessino A, Sivori S, Bottino C, Malaspina A, Morelli L, Moretta L . Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity. J Exp Med. 1998; 188(5):953-60. PMC: 3207313. DOI: 10.1084/jem.188.5.953. View

13.

Sasazuki T, Juji T, Morishima Y, Kinukawa N, Kashiwabara H, Inoko H . Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program. N Engl J Med. 1998; 339(17):1177-85. DOI: 10.1056/NEJM199810223391701. View

14.

Wu J, Song Y, Bakker A, Bauer S, Spies T, Lanier L . An activating immunoreceptor complex formed by NKG2D and DAP10. Science. 1999; 285(5428):730-2. DOI: 10.1126/science.285.5428.730. View

15.

Moretta L, Bottino C, Pende D, Vitale M, Mingari M, Moretta A . Different checkpoints in human NK-cell activation. Trends Immunol. 2004; 25(12):670-6. DOI: 10.1016/j.it.2004.09.008. View

16.

Yokoyama W, Kim S . Licensing of natural killer cells by self-major histocompatibility complex class I. Immunol Rev. 2006; 214:143-54. DOI: 10.1111/j.1600-065X.2006.00458.x. View

17.

Chen C, Busson M, Rocha V, Appert M, Lepage V, Dulphy N . Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders. Bone Marrow Transplant. 2006; 38(6):437-44. DOI: 10.1038/sj.bmt.1705468. View

18.

Igarashi T, Wynberg J, Srinivasan R, Becknell B, McCoy Jr J, Takahashi Y . Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells. Blood. 2004; 104(1):170-7. DOI: 10.1182/blood-2003-12-4438. View

19.

Aversa F, Velardi A, Tabilio A, Reisner Y, Martelli M . Haploidentical stem cell transplantation in leukemia. Blood Rev. 2001; 15(3):111-9. DOI: 10.1054/blre.2001.0157. View

20.

Beelen D, Ottinger H, Ferencik S, Elmaagacli A, Peceny R, Trenschel R . Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias. Blood. 2004; 105(6):2594-600. DOI: 10.1182/blood-2004-04-1441. View